Inspire Medical Systems Inc (INSP)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $1.77B
Last updated: Nov 17, 2026 at 11:06 AM ET
Inspire Medical Systems Inc (INSP) Financials: Revenue, Profit and Cash Flow
Inspire Medical Systems reported revenue of $911.98M for the fiscal year ended Dec 31, 2025, up 13.6% from the year before. That year, net income was $145.42M with a net margin of 15.9%, operating cash flow was $116.98M and free cash flow was $78.48M. The quarter ended Sep 30, 2026 had revenue of $206.69M and net income of -$24.39M.
Revenue and Margins
The operating margin was 5.6% in the fiscal year ended Dec 2025, the highest of the 9 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $16.43M, a compound annual rate of 56.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $911.98M | +13.6% | 85.4% | 5.6% | 15.9% |
| Dec 2024 | $802.80M | +28.5% | 84.7% | 4.5% | 6.7% |
| Dec 2023 | $624.80M | +53.2% | 84.5% | -6.4% | -3.4% |
| Dec 2022 | $407.86M | +74.7% | 83.8% | -11.7% | -11.0% |
| Dec 2021 | $233.39M | +102.3% | 85.7% | -17.1% | -18.0% |
| Dec 2020 | $115.38M | +40.6% | 84.7% | -48.7% | -49.6% |
| Dec 2019 | $82.05M | +62.2% | 83.4% | -42.5% | -40.5% |
| Dec 2018 | $50.59M | +77.1% | 80.1% | -40.3% | -43.1% |
| Dec 2017 | $28.57M | +73.9% | 78.9% | -56.0% | -61.3% |
| Dec 2016 | $16.43M | N/A | 76.2% | -105.0% | -112.8% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 171.8% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $911.98M | $802.80M | $624.80M | $407.86M | $233.39M | $115.38M | $82.05M | $50.59M | $28.57M | $16.43M |
| Cost of revenue | $133.22M | $122.99M | $96.58M | $66.11M | $33.28M | $17.62M | $13.64M | $10.06M | $6.02M | $3.90M |
| Gross profit | $778.76M | $679.82M | $528.22M | $341.74M | $200.12M | $97.76M | $68.41M | $40.54M | $22.55M | $12.52M |
| Research and development | $103.17M | $114.13M | $116.54M | $68.64M | $37.35M | $26.09M | $12.84M | $7.39M | $6.19M | $7.09M |
| Operating income | $50.95M | $36.08M | -$40.27M | -$47.59M | -$39.85M | -$56.21M | -$34.90M | -$20.38M | -$16.00M | -$17.25M |
| Net income | $145.42M | $53.51M | -$21.15M | -$44.88M | -$42.04M | -$57.20M | -$33.24M | -$21.83M | -$17.51M | -$18.53M |
| EBITDA | $59.37M | N/A | -$40.09M | -$45.79M | -$38.73M | -$55.22M | N/A | -$20.08M | -$15.36M | -$17.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $206.69M | $200.58M | $204.58M | $269.08M | $224.50M | $217.09M | $201.32M | $239.72M | $203.19M | $195.88M | $164.01M | $192.51M |
| Gross profit | $177.86M | $171.46M | $176.91M | $233.01M | $192.73M | $182.41M | $170.61M | $203.73M | $170.79M | $166.04M | $139.25M | $164.45M |
| Operating income | -$28.72M | -$514.00K | -$1.12M | $46.11M | $9.64M | -$3.32M | -$1.49M | $31.88M | $14.32M | $5.10M | -$15.22M | $9.30M |
| Net income | -$24.39M | $314.00K | -$11.29M | $136.09M | $9.93M | -$3.59M | $2.99M | $35.22M | $18.50M | $9.79M | -$10.01M | $14.76M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $2.16M by $102.66M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $907.32M | $808.38M | $676.81M | $564.88M | $295.08M | $281.19M | $181.25M | $200.08M | $25.09M | $13.12M |
| Current assets | $583.65M | $630.81M | $593.74M | $530.03M | $268.54M | $269.87M | $170.64M | $199.28M | $24.10M | $12.25M |
| Cash and equivalents | $104.81M | $150.15M | $185.54M | $441.59M | $214.47M | $190.52M | $22.86M | $97.29M | $8.96M | $6.68M |
| Total liabilities | $126.16M | $118.69M | $104.30M | $68.87M | $66.04M | $51.44M | $41.42M | $36.08M | $23.76M | $19.72M |
| Short-term debt | $2.16M | $1.75M | N/A | $1.34M | $9.19M | $0 | $828.00K | N/A | $16.46M | $3.31M |
| Long-term debt | N/A | N/A | N/A | N/A | $15.80M | $24.75M | $24.52M | $24.93M | $16.46M | $12.38M |
| Shareholder equity | $781.16M | $689.70M | $572.51M | $496.01M | $229.05M | $229.75M | $139.84M | $164.00M | $1.33M | -$6.61M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $953.03M | $925.99M | $911.38M | $918.49M | $807.72M | $802.19M | $730.81M | $808.38M | $796.19M | $728.39M | $685.84M | $676.81M |
| Total liabilities | $126.08M | $100.41M | $119.04M | $137.33M | $141.26M | $124.38M | $95.07M | $118.69M | $99.63M | $90.32M | $96.82M | $104.30M |
| Cash and equivalents | $190.80M | $127.76M | $98.93M | $104.81M | $112.84M | $106.93M | $53.88M | $150.15M | $147.51M | $188.03M | $175.42M | $185.54M |
| Shareholder equity | $826.95M | $825.58M | $792.34M | $781.16M | $666.46M | $677.81M | $635.74M | $689.70M | $696.56M | $638.07M | $589.02M | $572.51M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 67.1% of operating cash flow. Share repurchases came to 223.0% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $116.98M | $130.25M | $24.65M | $11.57M | -$20.12M | -$53.05M | -$32.85M | -$18.69M | -$15.79M | -$17.95M |
| Capital expenditures | $38.50M | $39.12M | $23.63M | $9.10M | $4.67M | $2.46M | $2.74M | $250.00K | $412.00K | $306.00K |
| Free cash flow | $78.48M | $91.12M | $1.02M | $2.47M | -$24.79M | -$55.50M | -$35.59M | -$18.94M | -$16.20M | -$18.25M |
| Share repurchases | $175.02M | $75.00M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $21.45M | -$113.12M | -$294.82M | -$19.60M | $29.14M | $86.63M | -$43.56M | -$83.39M | -$7.60M | -$306.00K |
| Financing cash flow | -$183.45M | -$52.39M | $13.95M | $235.08M | $14.95M | $134.06M | $1.96M | $190.38M | $25.66M | $12.81M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $46.43M | $23.23M | $12.85M | $52.47M | $68.53M | $2.68M | -$6.70M | $69.18M | $52.28M | -$78.00K | $8.86M | $17.27M |
| Capital expenditures | $7.54M | $9.16M | $9.73M | $10.66M | $10.44M | $9.00M | $8.41M | $7.03M | $8.01M | $12.39M | $11.70M | $8.03M |
| Free cash flow | $38.88M | $14.07M | $3.12M | $41.81M | $58.09M | -$6.31M | -$15.11M | $62.15M | $44.28M | -$12.47M | -$2.84M | $9.23M |
Frequently Asked Questions About INSP
What is Inspire Medical Systems' annual revenue?
Inspire Medical Systems reported revenue of $911.98M for the fiscal year ended Dec 31, 2025.
How fast is Inspire Medical Systems' revenue growing?
Revenue was up 13.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 30.8%.
Is Inspire Medical Systems profitable?
Yes. Inspire Medical Systems reported net income of $145.42M for the fiscal year ended Dec 31, 2025, with a net margin of 15.9%.
How much free cash flow does INSP generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $116.98M minus capital expenditures of $38.50M produced free cash flow of $78.48M.
How much debt does Inspire Medical Systems have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $2.16M and cash and equivalents of $104.81M.
INSP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts